Retatrutide · 39 amino acids

Retatrutide for Knee Pain: What the TRIUMPH-4 Trial Found


Retatrutide eased knee pain in a full phase 3 trial, now peer reviewed. On Nov 8, 2026, the New England Journal of Medicine published TRIUMPH-4: in 445 adults with knee osteoarthritis and obesity, retatrutide lowered knee pain scores by 3.96 and 3.74 points (9 mg and 12 mg) vs 2.12 points on placebo over 68 weeks, while body weight fell 20.0% and 23.7% vs 4.6%. A second trial, TRIUMPH-1-OA, pointed the same way. The honest catch: more people quit because of side effects, and retatrutide is still not approved.

Key facts

What TRIUMPH-4 actually tested

Knee osteoarthritis is joint wear that causes pain and stiffness, and extra body weight puts more load on the knee with every step. TRIUMPH-4 asked a simple question: if retatrutide (Lilly’s weekly shot that hits three hormone receptors, GIP, GLP-1 and glucagon) takes off a lot of weight, does knee pain follow?

The people in the trial were not young lifters. According to Healio, the average participant was 55.2 years old, 63.4% were women, and the average BMI was 40.4. Rheum-Live reports that 84.0% had a BMI of 35 or higher and everyone had moderate knee osteoarthritis on X-ray. All three groups, including placebo, got lifestyle counseling that included at least 150 minutes a week of moderate activity.

Pain was measured with WOMAC, a standard questionnaire for knee and hip arthritis that also scores physical function.

The results, in plain numbers

The NEJM paper uses a “hybrid” estimand as its main analysis, a method that counts most people even if their treatment changed. Healio also reported an “efficacy” analysis that looks at people who stayed on the drug as planned, which gives bigger numbers.

Retatrutide 9 mg Retatrutide 12 mg Placebo
Knee pain change (main analysis) -3.96 -3.74 -2.12
Knee pain change (on-treatment analysis) -4.48 -4.41 -2.43
Weight change (main analysis) -20.0% -23.7% -4.6%
Physical function change -4.1 -4.2 -2.1
No knee pain at week 68 (post hoc) 14.1% 12.0% 4.2%

Both doses beat placebo on pain (P < .001), and pain and function separated from placebo by week 16, the first time they were measured. Pooled across both trials, 69.6% (9 mg) and 63.2% (12 mg) of people cut their pain score at least in half by week 68, vs 37.8% on placebo.

One number to read carefully: Lilly’s headline of “up to 75.8%” less knee pain comes from a percent-change analysis that Lilly itself says was not pre-specified. The point changes above are the trial’s planned endpoints.

The second trial: TRIUMPH-1-OA

TRIUMPH-1-OA looked at 574 people with knee osteoarthritis inside Lilly’s larger obesity trial, testing 4 mg, 9 mg and 12 mg for 80 weeks. Pain scores improved by 1.35 to 1.77 points more than placebo, and weight fell 17.5% to 24.8% vs 4.3% on placebo. When the researchers counted everyone who started (intention to treat), the gains were smaller but still significant. Two trials pointing the same way is stronger evidence than one.

Side effects, honestly

The fine print

  1. Placebo helped too. The placebo group, which also got exercise and diet counseling, improved by 2.12 points. Retatrutide’s extra benefit is the gap, about 1.6 to 1.8 points.
  2. Not a joint repair study. People who needed a knee replacement were excluded, and the trials were not built to show slower joint damage or fewer replacements.
  3. Older, heavier population. This says little about a lean 28-year-old with a sports knee injury. The likely mechanism, per lead author Dr. Schnitzer, is simply less load: “you’re loading your knees less and therefore, there’s less pain.”
  4. Lilly-funded. Lilly paid for both trials and helped design them, analyze the data and write the paper.

For context, Rheum-Live notes that guidelines treat 5% to 10% weight loss as clinically meaningful for knee osteoarthritis, and these trials went well past that. Speaker Philip Conaghan also noted that no GLP-1 drug is FDA-approved for knee osteoarthritis pain today.

What it means for you

If you live with knee pain and carry extra weight, this is real, peer-reviewed good news: big weight loss looks like it brings real pain relief. But retatrutide is not approved and is not sold by any legitimate pharmacy, so anything marketed online under that name is an unapproved product. For where it stands with regulators, see when retatrutide may be available and the legal status tracker.

If your interest is recovery from a training injury rather than arthritis, our peptides for recovery guide grades the evidence for what people discuss there. For the bigger retatrutide picture, read what retatrutide is, its head-to-head results vs Ozempic, and the approved options in our semaglutide vs tirzepatide comparison. The right next step is a conversation with a licensed provider about your knees, your weight and the treatments that exist today.

Sources

Educational content only, not medical advice. Retatrutide is an investigational medicine and is not FDA-approved. Talk to a licensed provider about whether any medicine is right for you.

← All articles